Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-072694
Filing Date
2025-05-15
Accepted
2025-05-15 16:22:00
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5049
  Complete submission text file 0000950170-25-072694.txt   6867
Mailing Address 888 SEVENTH AVENUE 43RD FLOOR NEW YORK NY 10106
Business Address 888 SEVENTH AVENUE 43RD FLOOR NEW YORK NY 10106 212-705-8800
QVT Financial LP (Filed by) CIK: 0001290162 (see all company filings)

EIN.: 113694008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010
Business Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010 646-481-9832
Tourmaline Bio, Inc. (Subject) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92543 | Film No.: 25953724
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)